HIV-1 neutralization: Mechanisms and relevance to vaccine design

被引:41
作者
Zwick, Michael B. [1 ]
Burton, Dennis R. [1 ]
机构
[1] Scripps Res Inst, Dept Immunol, IMM 2, La Jolla, CA 92037 USA
关键词
neutralization mechanism; antibodies; vaccine development; virus fusion;
D O I
10.2174/157016207782418443
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody (Ab) mediated neutralization is a crucial means of host resistance to many pathogens and will most likely be required in the development of a vaccine to protect against HIV-1. Here we examine mechanistic aspects of HIV-1 neutralization with attention to recent Studies on the stoichiometric, kinetic and thermodynamic parameters involved. Neutralization of HIV-1, as with any microbe, minimally requires an initial molecular encounter with Ab. Ab occupancy of functional heterotrimers of the envelope glycoproteins, gp120 and gp41 (Env), indeed appears to be the dominant mechanism of neutralization for HIV-1. However, the Ab-binding site, the parameters mentioned above, as well as the stages and duration of vulnerability to Ab recognition, prior to and leading up to viral entry, each have a distinct impact on the mechanism of neutralization for any given Ab specificity. With HIV-1, the problems of mutational variation and neutralization resistance, coupled with the lability and conformational heterogeneity in Env, have stimulated the search for rational approaches to Env immunogen design that are unprecedented in vaccinology.
引用
收藏
页码:608 / 624
页数:17
相关论文
共 192 条
  • [51] V3: HIV's switch-hitter
    Hartley, O
    Klasse, PJ
    Sattentau, QJ
    Moore, JP
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (02) : 171 - 189
  • [52] Haynes Barton F., 2005, Human Antibodies, V14, P59
  • [53] Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Haynes, BF
    Fleming, J
    St Clair, EW
    Katinger, H
    Stiegler, G
    Kunert, R
    Robinson, J
    Scearce, RM
    Plonk, K
    Staats, HF
    Ortel, TL
    Liao, HX
    Alam, SM
    [J]. SCIENCE, 2005, 308 (5730) : 1906 - 1908
  • [54] Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site
    Herrera, C
    Spenlehauer, C
    Fung, MS
    Burton, DR
    Beddows, S
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (02) : 1084 - 1091
  • [55] Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex
    Herrera, Carolina
    Klasse, Per Johan
    Kibler, Christopher W.
    Michael, Elizabeth
    Moore, John P.
    Beddows, Simon
    [J]. VIROLOGY, 2006, 351 (01) : 121 - 132
  • [56] Humoral immunity to HIV-1: neutralization and beyond
    Huber, M.
    Trkola, A.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2007, 262 (01) : 5 - 25
  • [57] Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
    Igarashi, T
    Brown, C
    Azadegan, A
    Haigwood, N
    Dimitrov, D
    Martin, MA
    Shibata, R
    [J]. NATURE MEDICINE, 1999, 5 (02) : 211 - 216
  • [58] Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains
    Jolly, Clare
    Sattentau, Quentin J.
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (15) : 7873 - 7884
  • [59] IMPROVED METHODS FOR BUILDING PROTEIN MODELS IN ELECTRON-DENSITY MAPS AND THE LOCATION OF ERRORS IN THESE MODELS
    JONES, TA
    ZOU, JY
    COWAN, SW
    KJELDGAARD, M
    [J]. ACTA CRYSTALLOGRAPHICA SECTION A, 1991, 47 : 110 - 119
  • [60] Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Joos, B
    Trkola, A
    Kuster, H
    Aceto, L
    Fischer, M
    Stiegler, G
    Armbruster, C
    Vcelar, B
    Katinger, H
    Guenthard, HF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) : 1773 - 1779